Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia

AbstractBackgroundTo evaluate the efficacy of short-term lurasidone in antipsychotic treatment-naïve (TN) adolescents with schizophrenia versus those treated previously (TP) with antipsychotics.MethodsPatients aged 13–17 with schizophrenia, and a Positive and Negative Symptom Scale (PANSS) score ≥ 7...

Full description

Bibliographic Details
Main Authors: Christoph U. Correll, Michael Tocco, Jay Hsu, Robert Goldman, Andrei Pikalov
Format: Article
Language:English
Published: Cambridge University Press 2022-01-01
Series:European Psychiatry
Subjects:
Atypical antipsychotic
controlled clinical trial
lurasidone
schizophrenia
second generation antipsychotic
Online Access:https://www.cambridge.org/core/product/identifier/S0924933822000116/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S0924933822000116/type/journal_article

Similar Items